中国国际金融股份有限公司保荐代表人李邦新先生致辞

Group 1 - The core viewpoint is that Beixin Life has rapidly become a leader in China's medical device industry, focusing on cardiovascular precision intervention with innovative products [2] - Beixin Life's core products, the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, have entered the national special review procedure for innovative medical devices [2] - The company is the first domestic medical device company to have a combination of intravascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for clinical precision diagnosis of coronary artery disease in China [2] Group 2 - The underwriting and lead underwriting of Beixin Life's IPO is handled by China International Capital Corporation (CICC), which has witnessed the company's steady and rapid development and recognizes the management's industry insight and experience [2] - The company's technology platform, R&D system, and rich product pipeline lay a solid foundation for long-term development [2] - The IPO will inject more capital into Beixin Life, further promoting the industrialization of its core products and strengthening its global market layout [2]